Sol-Gel Technologies Announces Last Patient Last Visit In Pivotal Phase 3 Trial Of SGT-610 For Gorlin Syndrome; Says Top-Line Results On Track For Late November
Share
Why It Matters
Sol-Gel finished testing a new medicine for a rare disease. Watch for results in late November to see if it works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.